Abviris Home

Tumor marker

A blood based entire body screen to find HPV induced cancer early - all within minutes and by using just one drop of blood

Prevo-Check®

Rapid test for detecting HPV16 induced carcinomas early. Easy to use in doctor's practice.
Clinical specificity > 99%

White Papers

Learn more about screening for HPV induced cancer in the white paper series "Guidelines for identifying high-risk patients"

Online Courses

Interactive training resources on early detection of HPV-induced carcinomas

previous arrow
next arrow
Slider

Moving from cell to blood based HPV cancer screening.

Abviris offers a new patented generation of Immune Oncology Diagnostics for early detection of HPV induced cancer, allowing a blood based entire body screen within minutes just using one drop of blood.

Learn more about Prevo-Check®

News

New evidence demonstrates the potential of Prevo-Check® and tumour marker DRH1 for early detection of HPV-induced diseases

Our product Prevo-Check®, a patented test for the detection of HPV16-induced tumours, is the focus of two studies to be presented at the international HPV (human papilloma virus) congress EUROGIN on December 4-7. In a study conducted at the University of Graz, Dr. Weiland and colleagues discovered that Prevo-Check® is a rapid test for identifying …

Investors Convinced of Potential and Importance of a Novel Cancer Management Concept

Abviris GmbH Obtains Almost 3 Million Euros in Series A Financing Abviris GmbH commenced market entry in Germany after successful test-marketing phase (450 customers, 300,000 € revenues) and, respective clinical trials. Initial positioning is targeting screening for HPV induced tumours of head and neck and the anogenital region. Funds raised in round A reveal that …

Tumour marker for the early detection and therapy of HPV-induced anal cancer for HIV+ patients

A pilot study has compared serum samples of HIV+ patients before and after treatment of an HPV induced anal carcinoma using the Prevo-Check®. Prevo-Check® has been confirmed as a high quality test for the early detection and therapy of HPV induced anal cancer for HIV+ patients. Study participants showing a high Prevo-Check® result developed anal …

Events